Global Nanomedicine Market By Molecule Type (Nanoparticles, Nano Tubes, Nano Shells, and Nano Devices), By Indication (Clinical Oncology, Orthopedics, Clinical Cardiology, Infectious Diseases, and Other Indications), By Application, By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

In 2022, the global nanomedicine market was valued at US$ 139 billion and expected to grow US$ 358 billion in 2032. Between 2023 and 2032, this market is estimated to register the highest CAGR of 10.2%.

Nanomedicine is a medical application of nanotechnology that includes many applications, including tissue engineering, biosensors, diagnostic devices, and more. The commercialization and development of techniques that holds significant potential to improve the administration of drugs and disease management are anticipated to boost the adoption of nanomedicines, thereby increasing market growth. In addition, the market growth of nanomedicine is driven by the rising adoption of nanotechnology-based drug delivery methods coupled with the ineffectiveness of conventional therapeutics in treating disease.

Key Takeaways

• Market Growth: Nanomedicine market valued at US$ 139 billion in 2022, projected to reach US$ 358 billion by 2032, with a CAGR of 10.2%.
• Nanoparticles Dominance: Nanoparticles held a significant 74% revenue share in 2022, poised for the fastest growth, attributed to their versatile applications.
• Clinical Oncology Leadership: Clinical oncology led in 2022, capturing the largest market share, driven by the global rise in cancer prevalence.
• Drug Delivery Market Share: Drug delivery claimed the highest revenue share in 2022, benefiting from increased disease awareness and nanomedicine adoption.
• Therapeutics Segment Growth: The therapeutics segment is projected to grow significantly, boosted by technological advancements in nanotherapeutics.
• Market Drivers: The rising prevalence of chronic diseases propels market growth, particularly in addressing gaps between available treatments and patient needs.
• Cost-Related Restraints: High manufacturing and R&D costs pose challenges, impacting the market’s potential growth during the forecast period.
• Pharmaceutical Opportunities: Active involvement of pharmaceutical companies in nanoscience-based therapeutics presents significant growth opportunities for the nanomedicine industry.
• Government Funding Impact: Increased government funding, notably in North America, accelerates nanomedicine research, driving market expansion.
• Regional Dynamics: North America dominated with a 46% revenue share in 2022, while Asia Pacific is expected to expand significantly, fueled by increased public engagement.

Molecule Type Analysis

The nanoparticles segment held the largest revenue share in 2022

The nanomedicine market is segmented by molecule type into nanoparticles, nanotubes, nano shells, and nano devices. Among these segments, the nanoparticles segment dominated the market with a revenue share of 74% in 2022 and is also projected to grow at the fastest rate over the forecast period. This is mainly due to the benefits offered by various nanoparticles.

In addition, the segment growth is supported by increasing utilization of metal and metal oxide particles in photodynamic therapy (PDT) for cancer and infectious diseases treatment. Moreover, the nanoparticles can carry out various tasks because of their capacity to bind with chemical moieties in the form of scaffolds. In nanotechnology, the nanoparticles are used for selective binding by attaching them to ligands of the cell receptors. As a result, the demand for nanoparticles is increasing.

Indication Analysis

The clinical oncology segment dominated the global nanomedicine market

The indication channel further divides the market into clinical oncology, orthopedics, clinical cardiology, infectious diseases, and other indications. The clinical oncology segment accounted for the largest market share in 2022 and is expected to grow more potentially during the forecast period. The growth of this segment is primarily propelled by the rising prevalence of cancer globally. In addition, the growth is fueled by a wide range of cancer treatment products presently in clinical development stages.

Moreover, the need to develop more targeted cancer therapies is a significant factor anticipated to increase the research & development activities for clinical oncology. Furthermore, due to nanomedicine’s targeting efficiency and fewer side effects in cancer treatment, it has become a rapidly evolving treatment modality. As a result, the clinical oncology segment is expected to expand significantly in the coming years.

Application Analysis

The drug delivery segment dominated the global nanomedicine market in 2022

Based on application, the market is segmented into therapeutics, active implants, in-vivo imaging, in-vitro diagnostics, drug delivery, and implants. Among these applications, the drug delivery segment accounted for the largest revenue share in 2022. This significant market share is gained due to the rising number of diseases, including cancer, and increasing awareness among individuals regarding nanomedicine. Additionally, the use of nanotechnology in drug delivery can be attributed to the improvement in reticule-endothelial system evasion, favorable pharmacokinetics, and vivo dispersion, thereby propelling segment growth.

The therapeutics segment is projected to grow significantly during the forecast period, owing to several products that fit into this category for treating various ailments. This comprises the equipment, medications, and drug delivery systems. Moreover, advancements in technology helping the improvement of nanotherapeutics that can cross biological barriers are expected to surge the nanomedicine market growth during the forecast period.

Key Market Segments

Based on Molecule Type

• Nanoparticles
• Nano Tubes
• Nano Shells
• Nano Devices

Based on Indication

• Clinical Oncology
• Orthopedics
• Clinical Cardiology
• Infectious diseases
• Other Indications

Based on Application

• Therapeutics
• Active Implants
• In-vivo Imaging
• In-vitro Diagnostics
• Drug Delivery
• Implants

Drivers

The rising prevalence of chronic diseases surges the market growth

Nanomedicine is widely used in chronic disease treatment, such as diabetes, cardiovascular diseases, dementia, cancer, and other diseases, as it aids in the rapid metabolism of medicines in the body. Thus, the increasing prevalence of chronic diseases is anticipated to fuel market growth. Even though the healthcare and medicine sector has undergone incredible developments in past years, with the introduction of advanced therapies and products such as non-invasive surgical tools, advanced medical sensors, and portable imaging devices, there remains a wide gap between available treatments and patient needs.

The advances in nanomedicine aid in filling this gap. The nanomedicines are promising at delivering drugs to the target site in the right proportion and at an actual delivery rate. This is expected to cater well to the requirement of complicated disease conditions, potentially boosting the growth of the global nanomedicine market.

Restraints

High costs related to nanomedicine manufacturing and R&D hamper the market growth

There are rising concerns about the manufacturing costs, research and development activities for key players in the nanomedicine market, and market price for the end-user. The R&D necessitates many resources, raising worries about receiving funds. This significant investment is expected to be received by the innovator with significant profits, which result in increased cost of the product for end-user. As a result, the higher cost associated with nanomedicine will likely impede market growth during the forecast period.

Opportunity

Active participation of pharmaceutical companies in the development of novel Nano science-based therapeutics to generate significant growth opportunities

The advancements and expanding applications of nanotechnology in preventive interventions, early disease diagnosis, prophylaxis of acute and chronic disorders, and their prevention are the factors anticipated to surge the growth of the nanomedicine industry. The manufacturers mainly benefit from considerable growth prospects in the global nanomedicine market due to the rising demand for nanomedicines.

As a result, the field of nanomedicine is significantly expanding in the healthcare sector. Additionally, it is expected that the active involvement of major pharmaceutical companies in producing advanced nanoscience-based medicines will potentially contribute to the growth of this industry.

Trends

Increased government funding

Government organizations are expected to raise their research and development funding, opening attractive global nanomedicine market expansion opportunities. Moreover, government funding helps to accelerate massive capital-intensive projects. For instance, the Canadian Institutes of Health Research (CIHR) is funded by the government of Canada for research and development in regenerative medicine and nanomedicine.

This is likely to support the market growth of nanomedicine in the coming years. Moreover, the developments of novel technologies such as molecular nanotechnology, nanorobots, and nanovaccinology are expected to drive market growth positively.

Regional Analysis

North America accounted for the largest revenue share in 2022

Based on region, the global nanomedicine market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Out of these regions, North America dominated the nanomedicine market in 2022 with the highest revenue share of 46%. This significant market share can be attributed mainly to increasing alliances among businesses in this area and start-up nanomedicine companies.  Moreover, owing to government support and increased R&D expenditures, the region’s participation in the industrial sector has significantly increased.

In addition, the expansion of the nanomedicine market is mainly influenced by increased demand for prophylaxis of life-threatening illness and increased research funding in the United States. The Asia Pacific region is expected to expand significantly over the forecast period owing to the increased public engagement in consensus conferences related to nanoscience and nanotechnology.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

Emerging key players in the global nanomedicine market are highly focused on implementing various growth strategies to develop their portfolios and expand their presence in foreign markets. Several nanomedicine companies are concentrating on expanding their existing operations and increasing their spending on research & development activities.

Furthermore, they develop new products, collaborations, partnerships, competitive pricing, and mergers & acquisitions. In addition, several key players are presently focused on different marketing strategies, such as spreading awareness regarding nanomedicine, thereby propelling the target products’ growth.

Listed below are some of the most prominent nanomedicine industry players.

Market Key Players

• Abbott Laboratories
• Teva Pharmaceutical Industries Ltd.
• Nanospectra Biosciences, Inc.
• Celgene Corporation
• CombiMatrix Corporation
• Arrowhead Pharmaceuticals, Inc.
• Pfizer Inc.
• Merck & Co., Inc.
• Mallinckrodt Pharmaceuticals
• Other Key Players

Recent Developments

• In January 2022, NaNotics LLC announced a research collaboration with the Mayo Clinic to develop a NaNot that targets the soluble form of immune inhibitor PD-L1 that tumors produce.
• In August 2020, Innovasis, Inc. received authorization from the U.S. FDA for its three-dimensional printed implants used in spinal fusion surgery. Furthermore, in these implants, Promimic’s Hanano Surface Technology is used, which is a bioactive nano treatment for implant device surfaces resulting in enhanced molecular anchoring of the medical implants.

Report Scope